Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-08-20
Item 7.01
The disclosure centers on four executive personnel appointments effective August 20, 2026: Evan H. Jenkins promoted to Chief Administrative Officer (retaining Vice Chair and Secretary roles), J. Tyler Adkins promoted to General Counsel (retaining Assistant Secretary), Tyler H. Fields promoted to Assistant General Counsel, and Cameron H. Adkins hired as Director of Law, Finance, and Operations. These are material appointments to key leadership and legal positions that would affect investor assessment of the company's governance and operational structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-20
Item 5.02
The filing discloses both the departure of Thomas D. Schwenger (President and Chief Customer Officer since 2019) and the appointment of Dan Rizzo as EVP, Sales, Consulting, and Services, effective October 2, 2026. While both events occur, the principal action emphasized in the announcement is the appointment of Rizzo to fill the senior leadership role vacated by Schwenger's departure. The appointment of a named executive to a significant officer position is the salient disclosed event, making exec_appointment the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-20
Item 5.02
Thomas J. McInerney is returning from leave of absence to resume the role of President & Chief Executive Officer effective September 2, 2026, resuming day-to-day operational responsibilities and the principal executive officer role. While Jerome T. Upton's interim CEO role ends, the principal disclosed action is McInerney's appointment/return to the CEO position, making this an exec_appointment event. The change in principal executive officer is material to investors' assessment of company leadership and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-20
EX-99.1
The exhibit is a news release announcing the appointment of Prasanna Gopalakrishnan to CIBC's Board of Directors, effective September 1, 2026. This is a clear executive/board appointment disclosure. The appointee brings substantial relevant experience (30+ years in technology, data, cyber, and AI at major financial institutions including ADP, Sky, and Bank of America), making this material to investors assessing board composition and governance at a major North American financial institution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-20
Item 8.01
The filing discloses the appointment of Michael Richtmyer as Head of Operations for Manhattan Drug Company, Inc., a wholly owned subsidiary of Integrated BioPharma. The press release emphasizes his 35+ years of senior operations experience and his role leading "operational strategies and execution across MDC" with responsibility for manufacturing, supply chain, quality, and growth. This is a material executive appointment to a senior leadership position at a key operating subsidiary.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-20
The Board appointed two new directors, Mr. K. Brice "Rick" Toussaint and Mr. Bin Zhou, effective immediately on August 18, 2026. Both were also appointed to multiple board committees (Audit, Compensation, and Nominating & Corporate Governance), with Toussaint as Audit Committee Chair and Zhou as Compensation Committee Chair. This is a material governance event affecting board composition and committee leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
The Board of Directors approved the appointment of James Liddy as a director of the Company, effective immediately on August 19, 2026. This is a clear director appointment disclosed under Item 5.02, which is material to investors as board composition affects governance and oversight. The filing explicitly states there are no conflicting arrangements or related-party transactions, indicating a straightforward appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-20
Item 5.02
Taryn McHarg was appointed as Chief Financial Officer, effective upon the retirement of incumbent CFO Mark Haushill on March 31, 2027. Haushill will transition to a Senior Advisor role to provide continuity during the transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-20
Item 5.02
The filing discloses the appointment of François Vachon as Chief Executive Officer (effective August 13, 2026) and as a Board member (effective August 18, 2026), along with the appointment of Kurtis W. Winn to additional officer roles. While Lin Li's resignation as CEO and director is also disclosed, the principal action centers on the appointment of a new CEO with detailed compensation terms ($7,000–$10,000 monthly base salary, one-year term) and extensive responsibilities for governance, compliance, manufacturing oversight, and capital raising. This is a material executive appointment affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
The filing discloses the appointment of Michael D. Stein to the Board of Governors on August 19, 2026, to fill a vacancy. The principal action is a person taking a governance role, with assignment to three board committees (risk management, audit, and fixed assets). This is a clear executive appointment under Item 5.02 and is material to investors as board composition affects governance and oversight.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-08-20
EX-99.1
The exhibit announces the appointment of Finn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global Chief Operating Officer. While the document also discusses the amended earnout agreement and integration strategy, the principal disclosed actions are executive appointments to senior leadership roles. These appointments are material to investors as they reflect significant organizational restructuring and leadership changes following the Sanity acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
Ana Dutra was elected as an independent director of Tredegar Corporation and appointed to the Board's Executive Compensation Committee, effective August 17, 2026. The appointment strengthens the Board's governance and oversight capabilities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
The filing discloses the appointment of Gerri Martin-Flickinger to Victoria's Secret's Board of Directors, effective September 14, 2026, with the Board increasing from nine to ten directors. Ms. Martin-Flickinger, a former CTO at Starbucks with deep expertise in technology, digital transformation, and cybersecurity, will also serve on the Audit Committee. This is a clear director appointment under Item 5.02, and the press release emphasizes her strategic value to the company's technology and digital transformation priorities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
Lucky Lakhwindar Janda was appointed as a member of the Board of Directors of IMA Tech effective immediately on July 31, 2026, to fill an existing vacancy following the Board's expansion from one to two members. This is a clear executive appointment event. The disclosure is material because board composition changes affect governance and investor assessment of the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-19
Item 5.02
The filing discloses both a director retirement (Joe Householder, effective August 19, 2026) and a director appointment (Tim Ryan, effective August 19, 2026). While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure and the press release is the appointment of Tim Ryan to the Board, described as strengthening AMD's board with expertise in technology, enterprise operations, and financial governance. The retirement is presented as context for the appointment. Director appointments to major public companies are material governance events affecting board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-19
Item 5.02
Honeywell announced two executive appointments effective October 1, 2026: Billal Hammoud as President and CEO of Process Technology (succeeding Ken West) and Juan Picon as President and CEO of Building Automation (succeeding Hammoud). Both appointees are described as Honeywell veterans, and the company emphasized these appointments strengthen its leadership bench.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Mr. Patrick J. Burns was appointed to the Board of Directors of NACCO Industries effective August 19, 2026, with the Board size increasing from 11 to 12 members. The filing emphasizes his extensive executive experience as CEO and CFO across multiple industrial companies, and the Board's determination that he qualifies as an independent director. This is a material board appointment that would affect investor assessment of the company's governance and leadership composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
The Board approved the appointment of Tom Speir as Chief Financial Officer effective September 8, 2026, succeeding Jefferson L. Harralson. Speir's compensation package includes a $600,000 base salary, $215,000 sign-on bonus, and $450,000 sign-on equity grant, with Harralson remaining employed through December 31, 2026 for transition purposes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-19
Item 5.02
Rudy Rong was appointed as President of ZeroStack Corp., effective upon closing of the $1 billion strategic transaction, with a base salary of $500,000, a restricted stock grant of 125,000 shares, and severance provisions. The appointment represents a significant leadership change tied to the company's transformative capital transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Robert Beck was appointed as a director of Encore Capital Group effective August 19, 2026, with the Board increasing from 8 to 9 directors. Mr. Beck, a seasoned financial services executive with 30+ years of experience including prior CEO roles, was appointed to the Audit Committee and Risk Committee. This is a material executive appointment that would affect a reasonable investor's assessment of board composition and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-19
EX-99.1
On July 27, 2026, Javier Reyes, Chair of the Board, was appointed Interim Chief Executive Officer while the Board commenced a search for a permanent CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-08-19
Item 5.02
David Rivas was appointed Chief Operating Officer in a newly created role effective August 18, 2026, transitioning from Chief Technology Officer. Andrew Bestwick, Ph.D. was simultaneously appointed Chief Technology Officer. Both appointments represent material executive leadership changes affecting the registrant's governance and operational structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-19
Item 5.02
Nathan Tucker was appointed as Senior Vice President and Chief Financial Officer of Core Natural Resources, Inc. effective August 18, 2026, succeeding Mitesh Thakkar who expanded into an additional role. This C-suite appointment is material to investor assessment of company leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Baxter International appointed John Rogers as Executive Vice President and Chief Financial Officer, effective October 1, 2026. Rogers' compensation package includes a base salary of $925,000, target bonus of 100% of base, equity grants totaling $4,000,000 LTI target value, and a sign-on bonus of $2,827,629.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-19
Item 5.02
Scott Gleason was appointed as Chief Financial Officer and Treasurer effective August 31, 2026, with a base salary of $400,000, a $500,000 equity award, and a 40% bonus target. Gleason brings 25+ years of healthcare and capital markets experience to the role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Jimmy D. Ford was appointed as a Class III director on August 17, 2026, by the Class B Shareholders, with a term expiring at the 2029 annual meeting. He was also appointed to serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Longeveron appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer effective August 17, 2026. The filing discloses his extensive 25+ years of biopharma leadership experience, prior CFO roles at public biotech companies (Opus Genetics, Insilico Medicine, Journey Medical), and his compensation package including $400,000 base salary, 45% performance bonus target, and 300,000 RSUs vesting over three years. This is a material executive appointment to a principal officer role at a clinical-stage biotech company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
The Board elected Erik Olsson to serve as a director effective immediately on August 18, 2026. This is a clear appointment of a director to the Board, with Olsson's background as former Chairman, President and CEO of Mobile Mini and prior CEO of RSC Holdings indicating significant experience. The disclosure of his committee assignment (Audit Committee) and compensation arrangements confirms this is a material executive appointment under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-19
Item 5.02
The primary disclosed action in Item 5.02(d) is the appointment of Susan B. Zaunbrecher to the boards of directors of LCNB Corp. and LCNB National Bank, effective August 18, 2026. While Item 5.02(e) also discloses new Change in Control Agreements with named executive officers, the filing centers on the director appointment as the lead event. Zaunbrecher's extensive background in banking, legal affairs, and corporate governance at Fifth Third Bancorp makes this a material board composition change for a community bank.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
The Board appointed Matthew Spanjers as a director effective August 13, 2026, and also appointed him to the compensation committee. While the disclosure includes standard director compensation details (cash and equity grants), the principal disclosed action is the appointment of a new director with significant food and beverage industry experience (former Chief Growth Officer of Krispy Kreme, McKinsey advisor). The appointment is material as it represents a change in board composition and governance, and notably Spanjers is a designee of Gateway Superfood investment entities under a December 2025 Investment Agreement.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-08-19
The 6-K discloses the appointment of two independent directors to the Board effective August 12, 2026: Mr. Jiwen Huang and Mr. Chuanjiang Xiao, both elected to fill vacancies and serve on the nominating committee. While the filing also mentions two director resignations (Wang and Liao), the principal disclosed action is the appointment of new directors to fill those vacancies, making this an exec_appointment event. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-19
Item 5.02
The filing discloses the appointment of two independent directors—Wei-Chieh Hao (appointed August 16, 2026) and Richard T. Betts (appointed August 18, 2026)—to the Board, with Hao also appointed as Chairperson of the Corporate Governance and Nominating Committee and Compensation Committee, and Betts as Chairperson of the Audit Committee. While the section also reports two director departures (Wong and Cheng), the principal disclosed actions center on the new appointments and their committee leadership roles, which are material governance changes for a SPAC. The departures are noted as non-contentious and are secondary to the appointment narrative.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-19
The 6-K discloses the appointment of multiple new directors and officers effective August 19, 2026, including the appointment of Li Xiang and Liu Zhenyu as Independent Directors, and the continuation of Huang Hongwu as CEO/Chairman and Wang Xuefei as CFO. While two directors (Wang Zhiyong and Zhang Peng) also resigned, the principal disclosed action is the appointment of new board members and the restructuring of executive leadership, which is material to investors' assessment of governance and management continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-19
Item 5.02
Shun-Chih Chuang was appointed as Chief Financial Officer effective August 17, 2026, under a new Employment Agreement providing annual salary of $84,000 and 100,000 shares annually.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-19
Item 7.01
The filing announces the appointment of Tony Fabrizio as Director, Aerospace and Defense of VisionWave Holdings UK Ltd, a wholly-owned subsidiary. Although the position is at the subsidiary level rather than the parent company, Fabrizio is described as leading business development and sales activities across the United Kingdom and Europe as part of the Company's strategic expansion into international defense and aerospace markets. His 25+ years of defense sector experience and direct role in executing the Company's geographic expansion strategy make this a material executive appointment warranting disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Granite Ridge appointed two independent directors, John Cocke and Jonathan Adams, to the Board effective August 19, 2026, expanding the Board from seven to nine members and enabling the company to transition from a controlled company to a majority-independent board structure under NYSE listing standards. The appointments include equity compensation and indemnity agreements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Dr. Raj Talluri was appointed as President and Chief Executive Officer effective September 1, 2026, and elected to the Board of Directors effective August 17, 2026. The appointment includes compensatory arrangements with a base salary of $750,000, target bonus of 110%, and equity awards totaling $20 million, replacing an interim CEO with a permanent leader bringing significant prior experience from Enovix, Micron Technology, Qualcomm, and Texas Instruments.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Sam Mehta was appointed President and Chief Executive Officer of L3Harris Technologies effective immediately on August 17, 2026, and was also appointed to the Board of Directors. Mehta brings 25+ years of aerospace and defense experience and previously led the company's largest segments (SMS and CSD) representing 80% of revenue.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The filing discloses the election and appointment of two independent directors, Nicholas J. Ritter and Charles W. Sulerzyski, to Horizon Bancorp's Board of Directors effective August 17, 2026, increasing the board size from 11 to 13 members. Both individuals bring substantial banking and cybersecurity expertise and were assigned to key board committees (Enterprise Risk Management, Operations and Cyber Security, and Wealth Committees). This is a clear executive appointment event under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Vista Gold appointed Gavin Ferguson as Managing Director of Vista Gold Australia Pty Ltd., effective September 7, 2026. Ferguson brings 35+ years of international mining experience, most recently as General Manager of Nevada Gold Mines' Carlin Mining Complex, and will lead the company's flagship Mt Todd gold project development.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-17
Item 5.02
Matthew Sobczyk was promoted from Corporate Controller to Interim Chief Financial Officer effective August 14, 2026, succeeding Rashed Dewan who resigned from the CFO position. The appointment addresses the company's financial leadership continuity following the departure of the prior CFO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-17
Item 5.02
Matt White was appointed as Chief Financial Officer of Bakkt, Inc., effective August 17, 2026, succeeding Karen Alexander. The appointment includes material compensation terms: base salary of $300,000, 90,000 restricted stock units, 60,000 stock options at a $10.00 exercise price, and severance provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-17
Item 5.02
The disclosure centers on the appointment of David Sandberg to the Board of Directors effective immediately (Item 5.02(d)), with detailed background on his qualifications and investment holdings. While T. Allan McArtor's resignation is also disclosed (Item 5.02(b)), the substantive focus and length of the filing emphasizes the new director appointment. The appointment is material as it involves a change in board composition and a director with significant beneficial ownership stakes through Red Oak Partners' funds.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-17
Item 5.02
The disclosure centers on Nir Naor's appointment as principal financial and accounting officer on August 12, 2026, and his concurrent appointment as Corporate Secretary, with his title modified to Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer. While the section also mentions Francis X. Brown III's interim role ending, the principal action disclosed is Naor's appointment to key financial and governance roles. The appointment of a CFO and principal financial officer is material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-17
Item 5.02
The disclosure centers on Nadin Virani's appointment as interim Chief Financial Officer effective August 17, 2026, a material executive role. While Edmund Reese's transition from CFO is also disclosed, the principal action emphasized is Virani's appointment to fill the CFO position, supported by details of his background, compensation adjustment ($50,000/month increase), and bonus eligibility. This is a material change in senior leadership affecting investor assessment of the company's financial management.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Maze Therapeutics appointed two new directors to its Board: Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, both effective August 13, 2026. Both appointees bring substantial clinical and biopharmaceutical leadership experience, including prior roles at major pharmaceutical companies and academic institutions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-17
Item 5.02
Fred Stephan was appointed Chief Executive Officer and President effective November 1, 2026, following a deliberate Board succession process. The appointment includes his election as a Class III director and a comprehensive compensation package ($1.15M base salary, $1.44M short-term incentive target, $4.43M long-term incentive target, plus $3.77M and $2M RSU grants). Keith Harvey transitioned from CEO to Executive Chairman as part of this leadership succession.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-17
Item 5.02
CVS Health appointed Teresa Heitsenrether to its board of directors effective November 18, 2026. Heitsenrether is a senior executive from JPMorgan Chase with nearly forty years of financial services leadership experience, bringing expertise in data, analytics, and technology transformation to the company's board during a strategic transition period.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-17
Item 5.02
NNN REIT appointed Christina Chiu and Charles D. Mueller, Jr. to the Board of Directors effective October 1, 2026, as part of staged succession planning. Both appointees bring substantial REIT and executive leadership experience and will serve on the Audit Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 7.01
The filing discloses the appointment of Andra Frazier as Executive Vice President and Chief Credit Officer of CalPrivate Bank, announced via press release on August 17, 2026. This is a named executive appointment to a material C-suite position responsible for credit risk management at a $2.71 billion asset bank. The appointment of a Chief Credit Officer is material to investors assessing the registrant's risk management and governance structure.
View raw filing on EDGAR →